Drug
NLY01
NLY01 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
3
75%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
completed375%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
NCT07497399
completedphase_2
A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
NCT04154072
completedphase_2
A Study With NLY01 in Subjects With Type 2 Diabetes
NCT04159766
completedphase_1
A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects
NCT03672604
Clinical Trials (4)
Showing 4 of 4 trials
NCT07497399Phase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
NCT04154072Phase 2
A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
NCT04159766Phase 2
A Study With NLY01 in Subjects With Type 2 Diabetes
NCT03672604Phase 1
A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4